Food, Nutrition and Health Program, Faculty of Land and Food Systems, The University of British Columbia, 2205 East Mall, VancouverBC, V6T 1Z4, Canada.
British Columbia Children's Hospital Research Institute, 938 West 28th Avenue, VancouverBC, V5Z 4H4, Canada.
Br J Nutr. 2021 Dec 28;126(12):1823-1831. doi: 10.1017/S0007114521000581. Epub 2021 Feb 19.
Vitamin B12 (B12) is a co-enzyme essential for fetal growth and development. Lower maternal B12 status has been associated with preterm birth (<37 gestational weeks) and low birth weight (<2500 g), which are linked to morbidity and mortality across the lifespan. In Canada, 17-25 % of women in early pregnancy had a serum total B12 concentration <148 pmol/l and maternal total B12 concentration decreased throughout pregnancy. This study aimed to determine the association between maternal B12 status and birth outcomes in Canadian mother-newborn dyads. A secondary analysis of 709 mother-newborn dyads in British Columbia (BC), Canada, was conducted. Bio-banked first- (n 656) and second-trimester (n 709) maternal serum samples of apparently healthy South Asian (50 %) and European (50 %) women from the BC Prenatal Genetic Screening Program were quantified for B12 biomarkers (total B12, holotranscobalamin (holoTC), methylmalonic acid (MMA) and total homocysteine (tHcy)). Obstetric history and birth outcome data were obtained from the BC Perinatal Data Registry. All associations were determined using multiple linear regression. Maternal serum total B12, holoTC, MMA and tHcy had a mean weekly decrease of 3·64 pmol/l, 1·04 pmol/l, 1·44 nmol/l and 0·104 μmol/l, respectively (P < 0·001). Despite a total B12 concentration <148 pmol/l among 20-25 % of the women, maternal B12 biomarker concentrations were not associated with birth weight z-score, head circumference z-score and gestational age at birth (P > 0·05). Additional research in women at high risk of adverse birth outcomes and the association between maternal B12 status and functional, for example, cognitive, outcomes is needed.
维生素 B12（B12）是胎儿生长和发育所必需的辅酶。母体 B12 水平较低与早产（<37 孕周）和低出生体重（<2500 克）有关，这些问题会在整个生命周期中导致发病率和死亡率上升。在加拿大，17-25%的早孕期妇女血清总 B12 浓度<148 pmol/l，且母体总 B12 浓度在整个孕期逐渐降低。本研究旨在确定加拿大母婴对 B12 状态与出生结局之间的关联。对加拿大不列颠哥伦比亚省（BC）709 对母婴对的二次分析。不列颠哥伦比亚省产前基因筛查计划中，来自南亚（50%）和欧洲（50%）的看似健康的初产妇（n=656）和中产妇（n=709）的生物银行血清样本，其 B12 生物标志物（总 B12、全钴胺素（holoTC）、甲基丙二酸（MMA）和总同型半胱氨酸（tHcy））进行了定量分析。产科史和出生结局数据来自不列颠哥伦比亚省围产期数据登记处。所有关联均使用多元线性回归确定。母体血清总 B12、holoTC、MMA 和 tHcy 的每周平均下降值分别为 3.64 pmol/l、1.04 pmol/l、1.44 nmol/l 和 0.104 μmol/l（P<0.001）。尽管有 20-25%的妇女总 B12 浓度<148 pmol/l，但母体 B12 生物标志物浓度与出生体重 z 评分、头围 z 评分和出生时的胎龄无相关性（P>0.05）。需要在有不良出生结局高风险的妇女中开展更多研究，并研究母体 B12 状态与功能性结局（例如认知）之间的关联。
